PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
41 hedge funds and large institutions have $833K invested in PLx Pharma Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 11 closing their positions.
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
3% more funds holding
Funds holding: 40 → 41 (+1)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
80% less capital invested
Capital invested by funds: $4.11M → $833K (-$3.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
+$332K |
| 2 |
Jane Street
New York
|
+$80.6K |
| 3 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$73.8K |
| 4 |
HF
HRT Financial
New York
|
+$36.4K |
| 5 |
VF
Virtu Financial
New York
|
+$29.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$847K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$325K |
| 3 |
Two Sigma Advisers
New York
|
-$78.4K |
| 4 |
SRC
Shufro Rose & Co
New York
|
-$53K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$41.3K |
PLXP Hedge Fund Activity: Q4 2022 in Review
41 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q4 2022, worth a combined $833K — down 80% from $4.11M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PLXP positions and 11 closed out — a net gain of 2 holders — while 7 added to existing stakes and 12 trimmed.
The largest buyer was Steel Grove Capital Advisors, adding an estimated $332K. The largest seller was MSD Partners, exiting entirely with an estimated $847K sold.
- 41 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q4 2022, up from 40 in Q3 2022.
- Funds reported $833K of PLx Pharma Inc. Common Stock stock for Q4 2022, down 80% quarter-over-quarter.
- 13 funds opened new PLx Pharma Inc. Common Stock positions in Q4 2022 and 11 closed out, a net change of +2 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q4 2022 was Steel Grove Capital Advisors, an estimated $332K added.
- The largest PLx Pharma Inc. Common Stock seller in Q4 2022 was MSD Partners, an estimated $847K sold.
Based on aggregated 13F filings for Q4 2022.